Antibody Titer - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

Antibody Titer

The Experts below are selected from a list of 94938 Experts worldwide ranked by ideXlab platform

Antibody Titer – Free Register to Access Experts & Abstracts

Timothee Pelle – One of the best experts on this subject based on the ideXlab platform.

  • Anti-Phospholipase A 2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy
    Journal of the American Society of Nephrology, 2015
    Co-Authors: Piero Ruggenenti, Elena Gagliardini, Hanna Debiec, Barbara Ruggiero, Antonietta Chianca, Timothee Pelle, Flavio Gaspari, Flavio Suardi, Silvia Orisio, Ariela Benigni

    Abstract:

    Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary membranous nephropathy (MN), even after other treatments have failed. To assess the relationships among treatment effect, circulating nephritogenic anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies and genetic polymorphisms predisposing to Antibody production we serially monitored 24-hour proteinuria and Antibody Titer in patients with primary MN and long-lasting NS consenting to rituximab (375 mg/m(2)) therapy and genetic analyses. Over a median (range) follow-up of 30.8 (6.0-145.4) months, 84 of 132 rituximab-treated patients achieved complete or partial NS remission (primary end point), and 25 relapsed after remission. Outcomes of patients with or without detectable anti-PLA2R antibodies at baseline were similar. Among the 81 patients with antibodies, lower anti-PLA2R Antibody Titer at baseline (P=0.001) and full Antibody depletion 6 months post-rituximab (hazard ratio [HR], 7.90; 95% confidence interval [95% CI], 2.54 to 24.60; P

  • anti phospholipase a2 receptor Antibody Titer predicts post rituximab outcome of membranous nephropathy
    Journal of The American Society of Nephrology, 2015
    Co-Authors: Piero Ruggenenti, Hanna Debiec, Barbara Ruggiero, Antonietta Chianca, Timothee Pelle, Flavio Gaspari, Flavio Suardi, Elena Gagliardini

    Abstract:

    Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary membranous nephropathy (MN), even after other treatments have failed. To assess the relationships among treatment effect, circulating nephritogenic anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies and genetic polymorphisms predisposing to Antibody production we serially monitored 24-hour proteinuria and Antibody Titer in patients with primary MN and long-lasting NS consenting to rituximab (375 mg/m 2 ) therapy and genetic analyses. Over a median (range) follow-up of 30.8 (6.0–145.4) months, 84 of 132 rituximabtreated patients achieved complete or partial NS remission (primary end point), and 25 relapsed after remission. Outcomes of patients with or without detectable anti-PLA2R antibodies at baseline were similar. Among the 81 patients with antibodies, lower anti-PLA2R Antibody Titer at baseline (P=0.001) and full Antibody depletion 6 months post-rituximab (hazard ratio [HR], 7.90; 95% confidence interval [95% CI], 2.54 to 24.60; P,0.001) strongly predicted remission. All 25 complete remissions were preceded by complete anti-PLA2R Antibody depletion. On average, 50% anti-PLA2R Titer reduction preceded equivalent proteinuria reduction by 10 months. Re-emergence of circulating antibodies predicted disease relapse (HR, 6.54; 95% CI, 1.57 to 27.40; P=0.01), whereas initial complete remission protected from the event (HR, 6.63; 95% CI, 2.37 to 18.53; P,0.001). Eighteen patients achieved persistent Antibody depletion and complete remission and never relapsed. Outcome was independent of PLA2R1 and HLA-DQA1 polymorphisms and of previous immunosuppressive treatment. Therefore, assessing circulating antiPLA2R autoantibodies and proteinuria may help in monitoring disease activity and guiding personalized rituximab therapy in nephrotic patients with primary MN.

  • antiphospholipase a2 receptor Antibody Titer and subclass in idiopathic membranous nephropathy
    Journal of The American Society of Nephrology, 2012
    Co-Authors: Julia M Hofstra, Hanna Debiec, Timothee Pelle, Pierre Ronco, C D Short, Robert Kleta, Peter W Mathieson

    Abstract:

    The phospholipase A(2) receptor (PLA(2)R) is the major target antigen in idiopathic membranous nephropathy. The technique for measuring antibodies against PLA(2)R and the relationship between Antibody Titer and clinical characteristics are not well established. Here, we measured anti-PLA(2)R (aPLA(2)R) Antibody Titer and subclass in a well defined cohort of 117 Caucasian patients with idiopathic membranous nephropathy and nephrotic-range proteinuria using both indirect immunofluorescence testing (IIFT) and ELISA. We assessed agreement between tests and correlated Antibody Titer with clinical baseline parameters and outcome. In this cohort, aPLA(2)R antibodies were positive in 74% and 72% of patients using IIFT and ELISA, respectively. Concordance between both tests was excellent (94% agreement, ?=0.85). Among 82 aPLA(2)R-positive patients, Antibody Titer significantly correlated with baseline proteinuria (P=0.02). Spontaneous remissions occurred significantly less frequently among patients with high Antibody Titers (38% versus 4% in the lowest and highest tertiles, respectively; P<0.01). IgG4 was the dominant subclass in the majority of patients. Titers of IgG4, but not IgG1 or IgG3, significantly correlated with the occurrence of spontaneous remission (P=0.03). In summary, these data show high agreement between IIFT and ELISA assessments of aPLA(2)R Antibody Titer and highlight the pathogenetic role of these antibodies, especially the IgG4 subclass, given the observed relationships between aPLA(2)R Titer, baseline proteinuria, and outcome.

Hanna Debiec – One of the best experts on this subject based on the ideXlab platform.

  • Anti-Phospholipase A 2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy
    Journal of the American Society of Nephrology, 2015
    Co-Authors: Piero Ruggenenti, Elena Gagliardini, Hanna Debiec, Barbara Ruggiero, Antonietta Chianca, Timothee Pelle, Flavio Gaspari, Flavio Suardi, Silvia Orisio, Ariela Benigni

    Abstract:

    Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary membranous nephropathy (MN), even after other treatments have failed. To assess the relationships among treatment effect, circulating nephritogenic anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies and genetic polymorphisms predisposing to Antibody production we serially monitored 24-hour proteinuria and Antibody Titer in patients with primary MN and long-lasting NS consenting to rituximab (375 mg/m(2)) therapy and genetic analyses. Over a median (range) follow-up of 30.8 (6.0-145.4) months, 84 of 132 rituximab-treated patients achieved complete or partial NS remission (primary end point), and 25 relapsed after remission. Outcomes of patients with or without detectable anti-PLA2R antibodies at baseline were similar. Among the 81 patients with antibodies, lower anti-PLA2R Antibody Titer at baseline (P=0.001) and full Antibody depletion 6 months post-rituximab (hazard ratio [HR], 7.90; 95% confidence interval [95% CI], 2.54 to 24.60; P

  • anti phospholipase a2 receptor Antibody Titer predicts post rituximab outcome of membranous nephropathy
    Journal of The American Society of Nephrology, 2015
    Co-Authors: Piero Ruggenenti, Hanna Debiec, Barbara Ruggiero, Antonietta Chianca, Timothee Pelle, Flavio Gaspari, Flavio Suardi, Elena Gagliardini

    Abstract:

    Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary membranous nephropathy (MN), even after other treatments have failed. To assess the relationships among treatment effect, circulating nephritogenic anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies and genetic polymorphisms predisposing to Antibody production we serially monitored 24-hour proteinuria and Antibody Titer in patients with primary MN and long-lasting NS consenting to rituximab (375 mg/m 2 ) therapy and genetic analyses. Over a median (range) follow-up of 30.8 (6.0–145.4) months, 84 of 132 rituximabtreated patients achieved complete or partial NS remission (primary end point), and 25 relapsed after remission. Outcomes of patients with or without detectable anti-PLA2R antibodies at baseline were similar. Among the 81 patients with antibodies, lower anti-PLA2R Antibody Titer at baseline (P=0.001) and full Antibody depletion 6 months post-rituximab (hazard ratio [HR], 7.90; 95% confidence interval [95% CI], 2.54 to 24.60; P,0.001) strongly predicted remission. All 25 complete remissions were preceded by complete anti-PLA2R Antibody depletion. On average, 50% anti-PLA2R Titer reduction preceded equivalent proteinuria reduction by 10 months. Re-emergence of circulating antibodies predicted disease relapse (HR, 6.54; 95% CI, 1.57 to 27.40; P=0.01), whereas initial complete remission protected from the event (HR, 6.63; 95% CI, 2.37 to 18.53; P,0.001). Eighteen patients achieved persistent Antibody depletion and complete remission and never relapsed. Outcome was independent of PLA2R1 and HLA-DQA1 polymorphisms and of previous immunosuppressive treatment. Therefore, assessing circulating antiPLA2R autoantibodies and proteinuria may help in monitoring disease activity and guiding personalized rituximab therapy in nephrotic patients with primary MN.

  • antiphospholipase a2 receptor Antibody Titer and subclass in idiopathic membranous nephropathy
    Journal of The American Society of Nephrology, 2012
    Co-Authors: Julia M Hofstra, Hanna Debiec, Timothee Pelle, Pierre Ronco, C D Short, Robert Kleta, Peter W Mathieson

    Abstract:

    The phospholipase A(2) receptor (PLA(2)R) is the major target antigen in idiopathic membranous nephropathy. The technique for measuring antibodies against PLA(2)R and the relationship between Antibody Titer and clinical characteristics are not well established. Here, we measured anti-PLA(2)R (aPLA(2)R) Antibody Titer and subclass in a well defined cohort of 117 Caucasian patients with idiopathic membranous nephropathy and nephrotic-range proteinuria using both indirect immunofluorescence testing (IIFT) and ELISA. We assessed agreement between tests and correlated Antibody Titer with clinical baseline parameters and outcome. In this cohort, aPLA(2)R antibodies were positive in 74% and 72% of patients using IIFT and ELISA, respectively. Concordance between both tests was excellent (94% agreement, ?=0.85). Among 82 aPLA(2)R-positive patients, Antibody Titer significantly correlated with baseline proteinuria (P=0.02). Spontaneous remissions occurred significantly less frequently among patients with high Antibody Titers (38% versus 4% in the lowest and highest tertiles, respectively; P<0.01). IgG4 was the dominant subclass in the majority of patients. Titers of IgG4, but not IgG1 or IgG3, significantly correlated with the occurrence of spontaneous remission (P=0.03). In summary, these data show high agreement between IIFT and ELISA assessments of aPLA(2)R Antibody Titer and highlight the pathogenetic role of these antibodies, especially the IgG4 subclass, given the observed relationships between aPLA(2)R Titer, baseline proteinuria, and outcome.

Elena Gagliardini – One of the best experts on this subject based on the ideXlab platform.

  • Anti-Phospholipase A 2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy
    Journal of the American Society of Nephrology, 2015
    Co-Authors: Piero Ruggenenti, Elena Gagliardini, Hanna Debiec, Barbara Ruggiero, Antonietta Chianca, Timothee Pelle, Flavio Gaspari, Flavio Suardi, Silvia Orisio, Ariela Benigni

    Abstract:

    Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary membranous nephropathy (MN), even after other treatments have failed. To assess the relationships among treatment effect, circulating nephritogenic anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies and genetic polymorphisms predisposing to Antibody production we serially monitored 24-hour proteinuria and Antibody Titer in patients with primary MN and long-lasting NS consenting to rituximab (375 mg/m(2)) therapy and genetic analyses. Over a median (range) follow-up of 30.8 (6.0-145.4) months, 84 of 132 rituximab-treated patients achieved complete or partial NS remission (primary end point), and 25 relapsed after remission. Outcomes of patients with or without detectable anti-PLA2R antibodies at baseline were similar. Among the 81 patients with antibodies, lower anti-PLA2R Antibody Titer at baseline (P=0.001) and full Antibody depletion 6 months post-rituximab (hazard ratio [HR], 7.90; 95% confidence interval [95% CI], 2.54 to 24.60; P

  • anti phospholipase a2 receptor Antibody Titer predicts post rituximab outcome of membranous nephropathy
    Journal of The American Society of Nephrology, 2015
    Co-Authors: Piero Ruggenenti, Hanna Debiec, Barbara Ruggiero, Antonietta Chianca, Timothee Pelle, Flavio Gaspari, Flavio Suardi, Elena Gagliardini

    Abstract:

    Rituximab induces nephrotic syndrome (NS) remission in two-thirds of patients with primary membranous nephropathy (MN), even after other treatments have failed. To assess the relationships among treatment effect, circulating nephritogenic anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies and genetic polymorphisms predisposing to Antibody production we serially monitored 24-hour proteinuria and Antibody Titer in patients with primary MN and long-lasting NS consenting to rituximab (375 mg/m 2 ) therapy and genetic analyses. Over a median (range) follow-up of 30.8 (6.0–145.4) months, 84 of 132 rituximabtreated patients achieved complete or partial NS remission (primary end point), and 25 relapsed after remission. Outcomes of patients with or without detectable anti-PLA2R antibodies at baseline were similar. Among the 81 patients with antibodies, lower anti-PLA2R Antibody Titer at baseline (P=0.001) and full Antibody depletion 6 months post-rituximab (hazard ratio [HR], 7.90; 95% confidence interval [95% CI], 2.54 to 24.60; P,0.001) strongly predicted remission. All 25 complete remissions were preceded by complete anti-PLA2R Antibody depletion. On average, 50% anti-PLA2R Titer reduction preceded equivalent proteinuria reduction by 10 months. Re-emergence of circulating antibodies predicted disease relapse (HR, 6.54; 95% CI, 1.57 to 27.40; P=0.01), whereas initial complete remission protected from the event (HR, 6.63; 95% CI, 2.37 to 18.53; P,0.001). Eighteen patients achieved persistent Antibody depletion and complete remission and never relapsed. Outcome was independent of PLA2R1 and HLA-DQA1 polymorphisms and of previous immunosuppressive treatment. Therefore, assessing circulating antiPLA2R autoantibodies and proteinuria may help in monitoring disease activity and guiding personalized rituximab therapy in nephrotic patients with primary MN.